Centre for Drug Development: Strategy and portfolio

Our strategic priorities

Our ambition is to accelerate the delivery of the next generation of medicines to the patients who need them.

As the world's only charity-funded drug development facility, our strategy is uniquely focused by the drive for patient benefit. We are particularly interested in innovative projects, and our strengths are in:

  • First in class therapies
  • First in human clinical trials
  • Projects where we can use pharmacodynamic and stratification biomarker technologies to identify and progress new treatments which have the greatest potential for patient benefit

We maintain a broad portfolio across therapeutic modalities including antibodies, imaging agents, cell therapies, vaccines and targeted small molecules.

Our pipeline

PortfolioOur development portfolio contains 10 small molecule agents and 10 biologicals as of September 2017. Download the full pipeline or browse the agents below.

 

AGENT

TARGET/
TECHNOLOGY

PARTNER

INDICATIONS

DEVELOPMENT STAGE

SnMP

HO1

Kings College London

Solid, others tbc

Exploratory

STK-01

HPG-docetaxel

Sitka Biopharma

Bladder

Exploratory

BT1718

MT1-MMP

Bicycle Therapeutics

Solid, lung, sarcoma, breast

 Phase I

LY3143921

Cdc7

Lilly

Solid, colorectal, ovarian

Phase I

AZD3965

MCT1

AstraZeneca

Solid, prostate, non-Hodgkin lymphoma,B cell

Phase I

AT13148

AGC, ROCK

Astex Pharmaceuticals

Solid

Completed Phase I

Vandetanib/ Selumetinib

EGFR, VEGFR, MEK

AstraZeneca

Solid, lung

 Completed Phase I

AT9283

Aurora Kinase

Astex Pharmaceuticals

Paediatric solid

Completed Phase I

mIBG

NAT nor-adrenalin transporter

The Royal Marsden NHS Foundation Trust

Neuroblastoma

Phase II

AMG319

p110d PI3K

Amgen

Head and neck oropharyngeal

Phase II

AGENT

TARGET/
TECHNOLOGY

PARTNER

INDICATIONS

DEVELOPMENT STAGE

Tb535H

5T4 / T-cell engaging antibody (tribody)

Biotecnol

Solid tumours; including thoracic / lung cancers

Due Diligence

SCIB2

Vaccine NY-ESO-1

Scancell

Solid, lung

Due Diligence

MEDI3039

Recombinant protein TrailR2

MedImmune

Solid, colorectal, non-small cell lung

Exploratory

ATN658

Antibody uPAR

Monopar Therapeutics

Solid, colon, breast, lung, melanoma

Exploratory

AST-VAC2

Vaccine LAMP, hTERT

Asterias Biotherapeutics

Lung

Trial Set Up

BI-1206

Antibody CD32b, FcγRIIB

BioInvent and Bloodwise

Lymphoma, B cell, chronic lymphocytic leukaemia

Phase I

MOv18

Antibody α-folate R

Kings College London

Solid

Phase I

1RG CART

Cell therapy GD2

Great Ormond Street Hospital for Children

Neuroblastoma

Phase I

Dl-B4

Antibody CD19

Merck Serono

Lymphoma, B cell, chronic lymphocytic leukaemia

Completed Phase I

MVA-EBV1b

Vaccine EBNA-LMP2

University of Birmingham

Nasopharyngeal, lymphoma

Completed Phase I

Our track record of marketed drugs

Abiraterone

Discovered at the CRUK Cancer Therapeutics Unit at The Institute of Cancer Research, and developed by the Centre for Drug Development before licensing to Janssen Biotech, Abiraterone acetate (Zytiga®) is a hormonal therapy for prostate cancer.

Pemetrexed

Pemetrexed (Alimta®) is indicated for pleural mesothelioma and non-small cell lung cancer.
 
 

Temozolomide

One of our earliest successes, discovered by CRUK-funded scientists and developed by the CDD in the 1980s and 90s, Temozolomide (Temodal ®) is used worldwide as the frontline drug for glioblastoma and astrocytoma.

Etoposide phosphate

Etoposide phosphate (Etopophos®) is a drug used in small cell lung cancer and testicular tumours that no longer respond to other treatments.
 

Rucaparib

Discovered by CRUK scientists at the Northern Institute for Cancer Research in a programme built on breakthroughs from CRUK's basic science, we progressed the early development of the PARP inhibitor Rucaparib (Rubraca®).

Formestane

Formestane (Lentaron®) is a selective aromatase inhibitor that was indicated for the use in breast cancer, but was subsequently superseded by third-generation inhibitors such as letrozole.

Contact us

We are looking to partner with leading pharmaceutical and biotechnology companies and academic scientists who require resource, capabilities or expertise to develop new agents for the treatment of cancer.

Get in touch

Share this page